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Research
AbstrACt
Objective To determine the extent of agreement and 
patterns of disagreement between wound swab and tissue 
samples in patients with an infected diabetic foot ulcer 
(DFU).
Design Multicentre, prospective, cross-sectional study.
setting Primary and secondary care foot ulcer/diabetic 
outpatient clinics and hospital wards across England.
Participants Inclusion criteria: consenting patients aged 
≥18 years; diabetes mellitus; suspected infected DFU. 
Exclusion criteria: clinically inappropriate to take either 
sample.
Interventions Wound swab obtained using Levine’s 
technique; tissue samples collected using a sterile dermal 
curette or scalpel.
Outcome measures Coprimary: reported presence, and 
number, of pathogens per sample; prevalence of resistance 
to antimicrobials among likely pathogens. Secondary: 
recommended change in antibiotic therapy based on blinded 
clinical review; adverse events; sampling costs.
results 400 consenting patients (79% male) from 
25 centres. Most prevalent reported pathogens were 
Staphylococcus aureus (43.8%), Streptococcus (16.7%) 
and other aerobic Gram-positive cocci (70.6%). At least one 
potential pathogen was reported from 70.1% of wound swab 
and 86.1% of tissue samples. Pathogen results differed 
between sampling methods in 58% of patients, with more 
pathogens and fewer contaminants reported from tissue 
specimens. The majority of pathogens were reported 
significantly more frequently in tissue than wound swab 
samples (P<0.01), with equal disagreement for S. aureus 
and Pseudomonas aeruginosa. Blinded clinicians more often 
recommended a change in antibiotic regimen based on 
tissue compared with wound swab results (increase of 8.9%, 
95% CI 2.65% to 15.3%). Ulcer pain and bleeding occurred 
more often after tissue collection versus wound swabs (pain: 
9.3%, 1.3%; bleeding: 6.8%, 1.5%, respectively).
Conclusion Reports of tissue samples more frequently 
identified pathogens, and less frequently identified non-
pathogens compared with wound swab samples. Blinded 
clinicians more often recommended changes in antibiotic 
therapy based on tissue compared with wound swab 
specimens. Further research is needed to determine the 
effect of the additional information provided by tissue 
samples.
trial registration number ISRCTN52608451.
IntrODuCtIOn 
Diabetes mellitus is now a worldwide pandemic, 
with the prevalence in the USA now exceeding 
14%.1 In persons with diabetes, foot compli-
cations, most commonly ulceration related 
to peripheral sensory and motor neuropathy 
and peripheral arterial disease,2 3 occur in 
15%–25% during their lifetime.4 5 At presenta-
tion, over half of diabetic foot ulcers (DFU) are 
clinically infected6 and foot infection precedes 
approximately 80% of non-traumatic lower 
limb amputations.4 7 8 
strengths and limitations of this study
 ► The first appropriately powered prospective study to 
assess agreement between these two methods of 
wound culture sampling.
 ► Investigates the relationship between baseline 
characteristics and agreement between the types of 
specimen using multivariable modelling.
 ► Included a substudy to investigate the potential 
clinical relevance of the different amount of 
information gleaned from tissue and wound swab 
results by seeking opinion of blinded clinicians on 
whether the microbiology results indicate a need to 
change antibiotic therapy.
 ► This pragmatic study defined pathogens based 
on those reported by the clinical microbiology 
laboratory, so it  may not reflect all organisms/
isolates identified.
 ► Tissue collection and sample culturing methods 
were not standardised across hospital laboratories.
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Infection is a clinical diagnosis made using classification 
guidelines to help clinicians to determine infection severity.9 
Antibiotics are commonly initiated immediately (empirical 
treatment) and the results of samples collected for identifi-
cation of wound pathogens and their sensitivities are then 
used to tailor the antibiotic regimen, avoiding unnecessarily 
broad-spectrum therapy and antibiotic resistance.10–12 Accu-
rate culture results depend on collecting samples of infected 
tissue that is less likely to be contaminated by colonising 
flora. Sterile swabs for culture are widely available, quick and 
easy to use and can be collected by most types of healthcare 
personnel. Unfortunately, wound swabs typically sample 
superficial flora, including colonisers or contaminants, and 
because of their construction (usually cotton wool) may 
fail to grow anaerobic or fastidious pathogens. Recognising 
these limitations, many clinical microbiology laboratories 
offer only minimal processing of wound swabs. Alternatively, 
specimens may be collected by obtaining tissue from the 
base of the wound; this requires slightly more skill and time, 
but may reveal more pathogens and be less susceptible to 
contamination with non-pathogens. Despite exhortations 
to obtain tissue rather than wound swab samples from most 
authoritative guidelines,9 13 14 many clinicians default to the 
wound swab method. Our previous systematic review identi-
fied few studies comparing results of wound swabs and tissue 
samples,15 and these had limitations including retrospective 
designs, inclusion of patients with various types of wounds, 
small cohorts and lack of contemporaneous sampling. 
Uncertainty has not been resolved in subsequent studies. 
One study16 retrospectively reviewed 54 pairs of samples 
(from people with DFU but not all of whom had a wound 
infection) and reported that wound swabs detected more 
species than tissue samples—finding additional species in 
11.2% of cases, fewer species in 9.0% of cases and completely 
different organisms in 6.7%. In a second study, 50 patients 
with an infected DFU had both swab and tissue samples 
taken; with the latter considered the ‘gold-standard’, wound 
swabs had 100% sensitivity but <20% specificity.17 A third 
study, which collected specimens from 56 patients with an 
infected DFU, noted that wound swabs missed organisms 
identified from tissue specimens, especially Gram-negative 
bacteria, in patients with more severe infections.18
A further limitation of the published literature is that 
investigators have made the assumption that tissue speci-
mens are the ‘gold-standard’ for sampling, but this method 
may also miss wound flora. Hence, we proposed a study to 
assess agreement and extent of disagreement between the 
two methods of collecting wound specimens, by comparing 
the pathogens isolated from each method from the same 
wound.
MethODs
study design
We assessed the agreement between culture results 
of tissue and wound swab samples in patients with a 
suspected infected DFU. We have published a detailed 
description of the study methods.19
This was a multicentre, cross-sectional study of 400 people 
with diabetes mellitus in English primary and secondary 
care foot ulcer/diabetic outpatient clinics and hospital 
wards. Foot ulcer infection was diagnosed clinically based 
on signs and symptoms using Infectious Diseases Society 
of America/International Working Group on the Diabetic 
Foot (IDSA/IWGDF) criteria; patients were eligible for 
enrolment if the clinician evaluating them planned to 
treat them with antibiotic therapy. Consenting patients 
had a wound swab and tissue sample taken from the same 
foot ulcer. These were processed and reported by the usual 
local clinical microbiology laboratory so that the informa-
tion gathered would be relevant for clinical practice.
Coprimary endpoints were the extent of agreement 
between wound swab and tissue sampling for three micro-
biological parameters: (1) presence of isolates likely to 
be pathogens; (2) the number of bacterial pathogens 
reported per sample; and (3) the prevalence among 
likely pathogens of resistance to antimicrobials.
In addition, we investigated the clinical usefulness of 
the information provided by tissue versus wound swab 
samples using a blinded clinical review panel to interpret 
the microbiology results. Secondary objectives consid-
ered sampling-related adverse effects and the costs of 
sampling.
In a separate substudy, we investigated the clinical 
outcomes at 12 months after sampling and explored the 
prognostic factors related to ulcer healing.20
eligibility criteria
Patients were eligible if they had: a diagnosis of diabetes 
mellitus (type 1 or 2); were at least 18 years old; and had 
a suspected infected DFU (with or without bone infec-
tion, based on clinical signs and symptoms using IDSA/
IWGDF criteria and the judgement of the investigator). 
Patients were excluded if: the treating clinician deemed 
it inappropriate to take a tissue or wound swab sample 
for any reason; the patient had previously been recruited 
into the study; or they were unwilling or unable to provide 
informed consent. Patients were not excluded if they 
were currently being, or had recently been, treated with 
antimicrobial therapy.
Assessments
Sample acquisition
We trained clinicians at all centres to collect samples using 
the UK Health Protection Agency standards,21 22 which 
were subsequently updated,23 24 via site visits, and an 
e-Learning package that we developed for this purpose.25 
After wound cleansing and debridement (if required), a 
physician, nurse or podiatrist first obtained the wound 
swab sample from the infected ulcer using Levine’s tech-
nique.26 A tissue sample was subsequently collected using 
a sterile dermal curette or scalpel and placed in the trans-
port medium used locally. All samples were transferred 
to, and processed by, the centre’s local clinical microbi-
ology laboratory.21–24 Study samples received no special 
labelling or processing.
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Clinical assessments
Baseline data included a medical history and exam-
ination, including for any signs or symptoms of wound 
infection, previous treatments, and classifying the current 
status of the foot ulcer using the Perfusion, Extent, Depth, 
Infection and Sensation (PEDIS) scale,27 Wagner28 and 
Clinical Signs and Symptoms Classification of Infection 
systems,29 and investigators solicited level of pain in the 
ulcer immediately after each sample was obtained. Inves-
tigators reported adverse events associated with sample 
collection.
Centre differences questionnaire
Each participating site, including its microbiology labo-
ratory, completed a questionnaire regarding how they: 
acquired samples for culture; transported them to the 
laboratory; analysed the specimens; and reported the 
results to clinicians. We also requested that they report 
their local antibiotic protocols to allow evaluation of any 
potential differences among centres.
Clinical panel review
We compared the proportion of patients for whom the 
antibiotic regimen actually prescribed by the attending 
medical team was ‘appropriate’, based on culture and 
sensitivity results of wound swab or tissue samples. We sent 
microbiology results, along with a record of the empir-
ical antimicrobial regimen prescribed, for the first 250 
recruited patients (three were subsequently excluded due 
to protocol deviation or incomplete review) to a panel of 
13 senior clinicians who worked with a diabetic foot team 
and had antibiotic prescribing privileges. Each clinician 
received the results of cultures of patients’ wound swab 
or tissue sample on different occasions, and was blinded 
to whether results were from a tissue or wound swab 
specimen, and if they were from the same or different 
patients. Clinicians were asked:
1. ‘Are there any pathogens identified in the lab report 
that are not covered by the prescribed antimicrobial 
regimen? (Yes/No)’
2. ‘If you answered ‘yes’ to question 1, would knowing 
this information lead you to prescribe an alternative 
antibiotic regimen for this patient? (Yes/No)’
sample size
Our sample size was based on the primary outcome of the 
reported ‘presence or absence of a pathogen’. Our target 
sample size was 400, as we calculated that 399 patients 
would provide 80% power to detect a difference of ≥3% 
in the reported presence of a given pathogen, if overall 
prevalence was 10%, with 5% disagreement between the 
wound swab and tissue samples, using a two-sided McNe-
mar’s test at the 5% level of significance. This level of 
agreement would also provide a kappa statistic of 0.7. 
This calculation is based on lower prevalence organisms, 
such as Pseudomonas aeruginosa,30 hence the power was 
higher for more prevalent species.
statistical analysis
All tests of statistical significance were two sided and based 
on results from the evaluable population, with P values 
and 95% CIs provided as appropriate.
The various microbiology laboratories reported patho-
gens at a range of taxonomic levels, which we grouped by 
a previously developed scheme designed to report statis-
tics meaningfully, that is, by genus, species, and so on. For 
pathogens with a prevalence >8% we generated cross-tab-
ulations of reported presence in wound swab and tissue: 
overall percentage prevalence; agreement and disagree-
ment; unadjusted kappa for agreement; prevalence and 
bias-adjusted kappa for agreement; prevalence difference 
(tissue-wound swab, and 95% CI); and McNemar's test 
for differences. As the participating laboratories used a 
number of scales to quantify the extent of growth of a 
pathogen (eg, +/++/+++; +/++/+++/++++; scanty/light/
moderate/heavy; scanty/+/++/+++; light, moderate, 
heavy), we derived these onto one 3-point scale reported 
as +/++/+++. We used the derived data to tabulate the 
extent of bacterial growth (none, + to +++) and calculate 
weighted kappa statistics.
We prespecified baseline factors to investigate their rele-
vance in determining agreement between sample results, 
including: type of ulcer (ischaemic or neuroischaemic vs 
neuropathic); Wagner grade of ulcer (1–5); recent anti-
microbial therapy; and wound duration. We generated 
an overall summary of pathogens,31 and used univariable 
multinomial regression by centre to determine whether 
agreement was influenced by any of these factors.
Using univariable ordinal regression modelling we 
assessed the influence of baseline factors on the number 
of pathogens as follows: tissue sampling (compared with 
wound swab) had two or more extra pathogens reported; 
tissue sampling had one extra pathogen reported; tissue 
and wound swab sampling had the same number of 
pathogens reported; wound swab sampling had one or 
more extra pathogens reported. In both regression anal-
yses, we included centre as a random effect and multiple 
imputation to impute missing baseline factors.
For the clinical panel study of appropriateness of anti-
biotic treatment we summarised whether the pathogens 
reported were, or were not, covered by the actual treating 
clinician’s prescribed antimicrobial regimen. We also 
asked if, in the blinded clinician’s opinion, a change in 
antibiotic therapy was required. We used McNemar’s test 
to identify whether one sampling method identified more 
patients requiring a change in therapy than the other.
results
recruitment
Between 15 November 2011 and 15 May 2013 we screened 
680 patients, and enrolled 401 patients from 25 centres. 
We excluded one patient whose consent was lost and 
five for whom one or more sample was lost or misused, 
resulting in a full analysis set of 400 patients and an evalu-
able population of 395 patients (figure 1).
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Demographics
The recorded demographic characteristics of patients 
screened and those ultimately recruited were compa-
rable. Most patients were recruited from outpatient clinics 
(79.8%) and were male (79.0%). Recruited patients had a 
median age of 63 years (range 26–99), a median duration 
of diabetes of 16.8 years (IQR 9–23) and median duration 
of their index ulcer of 5.6 months (IQR 0.7–6.0). Before 
sampling, 60.3% had an antimicrobial dressing or agent 
applied on the suspected infected ulcer, and 46.8% had 
received some type of systemic antibiotic therapy. After 
enrolment, 93.5% of patients received systemic antibiotic 
therapy (table 1).
Microbiology results
Culture results yielded 79 different types of microbial 
isolates. Among the wound swab samples, there were no 
isolates reported from 20.0% and non-pathogenic isolates 
from 9.9%. Among tissue samples, there were no isolates 
reported in 10.1% and non-pathogenic isolates from 
3.8% (table 2).
The most frequently reported groups of pathogens 
were: Gram-positive cocci (70.6%); Gram-negative bacilli 
(36.7%); Enterobacteriaceae, including coliforms (26.6%); 
obligate anaerobes (23.8%); and Gram-positive bacilli 
(11.1%). The most frequently reported pathogens 
were: Staphylococcus aureus (43.8%, of which 8.1% were 
methicillin resistant); Streptococcus (16.7%); Enterococcus 
(14.9%); coagulase-negative Staphylococcus (12.2%); Cory-
nebacterium (9.4%); and P. aeruginosa (8.6%). All other 
genus and species level pathogens had a combined prev-
alence <6% (table 2).
Primary endpoints
Summary of pathogens reported
For 58.0% of patients there was a difference in the patho-
gens reported by the two sampling techniques. The wound 
swab reported additional pathogens to those in the tissue 
sample in 8.1%; the tissue sample reported additional 
pathogens to those in the wound swab in 36.7%; and the 
tissue and wound swab samples reported different patho-
gens, with or without overlap, in 13.2%.
Figure 1 Study recruitment diagram. MRSA, methicillin-resistant Staphylococcus aureus. 
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Reported presence of pathogens
The majority of pathogens were reported significantly 
more frequently in the tissue than the wound swab 
samples (P<0.01). For isolates of S. aureus and P. aerugi-
nosa, however, there was equal disagreement, meaning 
that for the same number of patients wound swabbing 
missed a pathogen reported by tissue sampling, as there 
were pathogens missed by tissue sampling but reported by 
wound swabbing. A full cross-tabulation of the reported 
presence of all of these pathogens is shown in table 2, 
with statistical analyses presented in table 3.
We examined whether the outcome ‘both wound swab 
and tissue report the same pathogens’ was related to any 
of several potentially important patient baseline vari-
ables (table 4). Based on a summary of our results we 
performed a univariable multinomial analysis and found 
that none of the baseline factors examined had a signifi-
cant effect on overall agreement.
Reported presence of antimicrobial resistance among likely 
pathogens
We investigated the reported presence of three common 
antimicrobial-resistant pathogens using two sampling 
methods. Methicillin-resistant S. aureus was reported in 
6.8% of wound swabs and 7.8% of tissue samples, a differ-
ence of 1.0% (95% CI −0.2% to 2.8%, McNemar’s exact 
P value=0.219). Vancomycin-resistant Enterococcus was 
reported in only one (0.3%) patient (detected by both 
wound swab and tissue). 
Number of pathogens reported per sample
Comparing the number of pathogens isolated from tissue 
versus wound swab specimens, both had a median of 1.0 
pathogen per sample, but the means were 1.5 and 1.0 
and the maximum numbers were 6 and 4 pathogens, 
respectively. A greater proportion of wound swab samples 
reported no pathogens compared with tissue samples 
(29.9% vs 13.9%, respectively). In terms of number of 
pathogens reported for the tissue versus the wound swab 
sample, for 49.6% of patients they were the same, for 
41.5% there was at least one more pathogen reported 
Table 1 Baseline characteristics of enrolled patients
Characteristic Clinical values
Full analysis 
set  
(n=400)
Age (years) Mean (SD) 63.1 (13.3)
Median, [range] 
and (IQR)
63.0 [26-99] 
(54.0, 73.0)
Sex Male 316 (79.0%)
Female 84 (21.0%)
Ethnicity White 377 (94.3%)
Other 23 (5.7%)
Site of recruitment Hospital ward 53 (13.3%)
Outpatient clinic 319 (79.8%)
Community clinic 28 (7.0%)
Diabetes type Type 1 58 (14.5%)
Type 2 342 (85.5%)
Duration of diabetes 
(years)
n Missing 3
Mean (SD) 16.8 (11.0)
Median, [range] 
and (IQR)
15.0 [0.04–57) 
(9.0, 23.0)
Diabetes treatment 
details
Oral 
hypoglycaemic 
agent
107 (27.8%)
Insulin 168 (43.6%)
Oral 
hypoglycaemic 
agent and insulin
109 (28.3%)
Other 1 (0.3%)
None 15 (3.8%)
Number of foot ulcers 1 268 (67.0%)
≥2 132 (33.0%)
Duration of index ulcer 
(months)
n Missing 4
Mean (SD) 5.58 (12.28)
Median,[range] and 
(IQR)
1.84 [0.1–
144.0] (0.69, 
6.00)
Aetiology of index 
ulcer
Ischaemic 14 (3.5%)
Neuropathic 202 (50.5%)
Ischaemic and 
neuropathic
182 (45.5%)
Missing 2 (0.5%)
Antimicrobial dressing 
on ulcer
Yes 241 (60.3%)
No 154 (38.5%)
Missing 5 (1.3%)
Patient already on 
systemic antibiotics
Yes 187 (46.8%)
No 194 (48.5%)
Missing 19 (4.8%)
Patient on antibiotics 
immediately after 
sampling
Yes 374 (93.5%)
No 26 (6.5%)
Continued
Characteristic Clinical values
Full analysis 
set  
(n=400)
Grade (Wagner scale)* Grade 1 136 (34.0%)
Grade 2 134 (33.5%)
Grade 3 122 (30.5%)
Grade 4 7 (1.8%)
Grade 5 1 (0.3%)
*Grade 1—superficial diabetic ulcer (partial or full thickness); 
grade 2—ulcer extension ligament, tendon, joint capsule, or deep 
fascia without abscess or osteomyelitis; grade 3—deep ulcer with 
abscess, osteomyelitis or joint sepsis; grade 4—gangrene localised 
to portion of forefoot or heel; grade 5—extensive gangrenous 
involvement of the entire foot.
Table 1 Continued 
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from the tissue than the wound swab sample, and for 
8.9% there was at least one more pathogen reported from 
the wound swab than the tissue sample.
By univariable ordinal analysis we found that patients’ tissue 
samples were reported to have two or more additional patho-
gens significantly more often if their ulcer was present for ≥56 
days than if it was present <56 days (OR 1.56, 95% CI 1.05 to 2.33, 
P=0.024).
Clinical panel review
In 73.3% of the cases reviewed by the blinded panel there 
was moderate agreement on the requirement for a change 
Table 2 Cross-tabulation of reported presence of at least one pathogen and pathogens with >8% prevalence in order of 
taxonomic rank and prevalence
Pathogen (overall prevalence)
Tissue results Tissue results
TotalNot reported Reported
At least one pathogen (88.1%) Swab Not reported 47 (11.9%) 71 (18.0%) 118 (29.9%)
Swab Reported 8 (2.0%) 269 (68.1%) 277 (70.1%)
Total 55 (13.9%) 340 (86.1%) 395 (100.0%)
Gram-positive cocci (70.6%) Swab Not reported 116 (29.4%) 68 (17.2%) 184 (46.6%)
Swab Reported 14 (3.5%) 197 (49.9%) 211 (53.4%)
Total 130 (32.9%) 265 (67.1%) 395 (100.0%)
Gram-negative bacilli (36.7%) Swab Not reported 250 (63.3%) 49 (12.4%) 299 (75.7%)
Swab Reported 12 (3.0%) 84 (21.3%) 96 (24.3%)
Total 262 (63.3%) 133 (33.7%) 395 (100.0%)
Enterobacteriaceae (including coliforms) (26.6%) Swab Not reported 290 (73.4%) 37 (9.4%) 327 (82.8%)
Swab Reported 14 (3.5%) 54 (13.7%) 68 (17.2%)
Total 304 (77.0%) 91 (23.0%) 395 (100.0%)
Obligate anaerobes (23.8%) Swab Not reported 301 (76.2%) 46 (11.6%) 347 (87.8%)
Swab Reported 19 (4.8%) 29 (7.3%) 48 (12.2%)
Total 320 (81.0%) 75 (19.0%) 395 (100.0%)
Gram-positive bacilli (11.1%) Swab Not reported 351 (88.9%) 40 (10.1%) 391 (99.0%)
Swab Present 1 (0.3%) 3 (0.8%) 4 (1.0%)
Total 352 (89.1%) 43 (10.9%) 395 (100.0%)
Streptococcus (16.7%) Swab Not reported 329 (83.3%) 18 (4.6%) 347 (87.8%)
Swab Reported 5 (1.3%) 43 (10.9%) 48 (12.2%)
Total 334 (84.6%) 61 (15.4%) 395 (100.0%)
Enterococcus (excluding VRE) (14.9%) Swab Not reported 336 (85.1%) 34 (8.6%) 370 (93.7%)
Swab Reported 6 (1.5%) 19 (4.8%) 25 (6.3%)
Total 342 (86.6%) 53 (13.4%) 395 (100.0%)
Coagulase-negative Staphylococcus (12.2%) Swab Not reported 347 (87.8%) 39 (9.9%) 386 (97.7%)
Swab Reported 1 (0.3%) 8 (2.0%) 9 (2.3%)
Total 348 (88.1%) 47 (11.9%) 395 (100.0%)
Corynebacterium (9.4%) Swab Not reported 358 (90.6%) 33 (8.4%) 391 (99.0%)
Swab Reported 1 (0.3%) 3 (0.8%) 4 (1.0%)
Total 359 (90.9%) 36 (9.1%) 395 (100.0%)
Pseudomonasaeruginosa (8.6%) Swab Not reported 361 (91.4%) 8 (2.0%) 369 (93.4%)
Swab Reported 8 (2.0%) 18 (4.6%) 26 (6.6%)
Total 369 (93.4%) 26 (6.6%) 395 (100.0%)
Staphylococcusaureus (excluding MRSA) (35.7%) Swab Not reported 254 (64.3%) 16 (4.1%) 270 (68.4%)
Swab Reported 16 (4.1%) 109 (27.6%) 125 (31.6%)
Total 270 (68.4%) 125 (31.6%) 395 (100.0%)
Methicillin-resistant S. aureus (8.1%) Swab Not reported 363 (91.9%) 5 (1.3%) 368 (93.2%)
Swab Reported 1 (0.3%) 26 (6.6%) 27 (6.8%)
Total 364 (92.2%) 31 (7.8%) 395 (100.0%)
MRSA, methicillin-resistant Staphylococcus aureus; VRE, vancomycin-resistant Enterococcus.
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in therapy between the wound swab and the tissue samples 
(kappa 0.45, 95% CI 0.34 to 0.56). In 17.8% of cases the 
blinded clinician indicated that the tissue sample results 
would lead to a recommendation of change in therapy, 
while the wound swab sample would not indicate a need 
for change. In 8.9% of cases the blinded clinician indi-
cated that the wound swab result would lead to a change 
in therapy whereas the tissue sample would not (increase 
of 8.9%, 95% CI 2.7% to 15.3%).
Adverse events
Investigators reported ‘bleeding of concern’ during 
sample collection in 30 (7.6%) of the recruited patients; 
it was attributed to the wound swab in six patients (1.5%) 
and to tissue sampling in 27 patients (6.8%). Higher levels 
of pain after either wound swab or tissue sampling were 
reported by 42 (10.5%) of patients. Of these, five (1.3%) 
patients reported worse pain after wound swabbing 
compared with tissue sampling, and 37 (9.3%) patients 
reported worse pain after tissue sampling compared with 
wound swabbing.
Centre differences
We received responses to our questionnaires from 22 
centres. Regarding the tissue sampling technique, one 
site used a dermal curette to collect tissue samples and 
others used a scalpel. There were no differences in the 
amount of time for a wound swab and a tissue sample to 
reach the microbiology laboratory from the clinic and 
no difference in the time it took from the receipt of the 
samples to processing. Among responding centres, 4 of 
17 (23.5%) reported slightly more urgent processing of 
tissue samples.
Microbiology laboratories performed a Gram-stained 
smear of the specimen more frequently for tissue than 
wound swab samples; of 19 laboratories, 9 (47.4%) did 
this for tissue only, 3 (15.8%) did it for both samples and 
6 (31.6%) did not routinely perform Gram staining (but 
offered it on request in one laboratory). Of 18 laborato-
ries, 10 (55.6%) reported all isolates grown from a tissue 
sample but tailored wound swab sample reports according 
to clinical details and likely microbiological significance 
of the isolates. Centre differences were apparent in the 
multinomial and ordinal regression analysis where its 
inclusion improved the fit of both models (P<0.001).
Because only two microbiology laboratories provided 
data on the cost of processing specimens, it was not 
possible for us to do an analysis by specimen type.
DIsCussIOn
To our knowledge, this is the largest comparison of the 
two main methods of sampling an infected DFU, the 
first to report detailed data on paired samples for each 
pathogen from paired samples and the first to examine 
the relationship between baseline characteristics and 
agreement between microbiology results by types of spec-
imen using multivariable modelling.
We found that tissue sampling had a higher yield than 
wound swab specimens, hence providing more infor-
mation on wound flora. While tissue sampling overall 
detected more organisms than wound swabs, both tech-
niques missed some organisms. Thus, to some degree 
they provide complementary information and both 
techniques may be useful. The differences in the results 
Table 3 Summary of agreement and disagreement statistics for most prevalent pathogens and the report of at least one 
pathogen
Overall 
prevalence
Overall 
disagreement Difference (95% CI)*
McNemar’s 
P value
Overall 
agreement
Unadjusted kappa 
(95% CI) PABAK
At least one pathogen 88.1% 20.0% 15.9% (11.8% to 20.1%) <0.0001 80.0% 0.44 (0.34 to 0.53) 0.60
Gram-positive cocci 70.6% 20.8% 13.7% (9.4% to 18.0%) <0.0001 79.2% 0.57 (0.50 to 0.65) 0.58
Gram-negative bacilli 36.7% 15.4% 9.4% (5.6% to 13.1%) <0.0001 84.6% 0.63 (0.55 to 0.71) 0.69
Enterobacteriaceae 
(including coliforms)
26.6% 12.9% 5.8% (2.3% to 9.3%) 0.0013 87.1% 0.60 (0.50 to 0.70) 0.74
Obligate anaerobes 23.8% 16.5% 6.8% (2.9% to 10.8%) 0.0008 83.5% 0.38 (0.26 to 0.50) 0.67
Gram-positive bacilli 11.1% 10.4% 9.9% (6.9% to 13.5%) <0.0001† 89.6% 0.11 (−0.01 to 0.23) 0.79
Streptococcus 16.7% 5.8% 3.3% (0.9% to 5.6%) 0.0067 94.2% 0.76 (0.66 to 0.85) 0.88
Enterococcus (excluding 
VRE)
14.9% 10.1% 7.1% (4.0% to 10.1%) <0.0001 89.9% 0.44 (0.30 to 0.58) 0.80
Coagulase-negative 
Staphylococcus
12.2% 10.1% 9.6% (6.7% to 12.9%) <0.0001† 89.9% 0.26 (0.11 to 0.41) 0.80
Corynebacterium 9.4% 8.6% 8.1% (5.4% to 11.2%) <0.0001† 91.4% 0.13 (−0.01 to 0.28) 0.83
Pseudomonas aeruginosa 8.6% 4.1% 0.0% (−2.0% to 2.0%) 1.0000 95.9% 0.67 (0.52 to 0.82) 0.92
Staphylococcusaureus 
(excluding MRSA)
35.7% 8.1% 0.0% (−2.8% to 2.8%) 1.0000 91.9% 0.81 (0.75 to 0.87) 0.84
*Tissue-swab.
†Exact P value/CI.
MRSA, methicillin-resistant Staphylococcus aureus; PABAK, prevalence and bias-adjusted kappa; VRE, vancomycin-resistant Enterococcus. 
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Table 4 Multinomial and ordinal regression models for individually fitted baseline factors
OR (95%  CI) AIC§ 
Reduction in
−2 Log L df P value
Multinomial summary of 
isolates
Both swab and tissue report 
the same pathogens.
Null model 941.29
Ulcer type* 945.72 1.570 3 0.666
  Any ischaemic versus 
neuropathic only
Swab>pathogens compared 
with the tissue
1.03 (0.48 to 2.20)
  Any ischaemic versus 
neuropathic only
Tissue>pathogens compared 
with the swab
0.86 (0.53 to 1.40)
  Any ischaemic versus 
neuropathic only
Swab and tissue report totally 
different pathogens.
0.68 (0.35 to 1.31)
Ulcer grade 949.16 4.125 6 0.660
  Grade 2 versus grade 1 Swab>pathogens compared 
with the tissue
0.68 (0.26 to 1.78)
  Grade 2 versus grade 1 Tissue>pathogens compared 
with the swab
1.08 (0.60 to 1.93)
  Grade 2 versus grade 1 Swab and tissue report totally 
different pathogens.
1.14 (0.51 to 2.54)
  Grade 3/4/5 versus grade 1 Swab>pathogens compared 
with the tissue
1.28 (0.52 to 3.11)
  Grade 3/4/5 versus grade 1 Tissue>pathogens compared 
with the swab
1.60 (0.87 to 2.95)
  Grade 3/4/5 versus grade 1 Swab and tissue report totally 
different pathogens.
1.55 (0.69 to 3.45)
Previous antibiotic therapy* 946.28 1.005 3 0.800
  Yes versus no Swab>pathogens compared 
with the tissue
0.80 (0.36 to 1.80)
  Yes versus no Tissue>pathogens compared 
with the swab
1.14 (0.69 to 1.89)
  Yes versus no Swab and tissue report totally 
different pathogens.
1.10 (0.56 to 2.16)
Antimicrobial dressing* 943.44 3.850 3 0.278
  Yes versus no Swab>pathogens compared 
with the tissue
1.13 (0.51 to 2.51)
  Yes versus no Tissue>pathogens compared 
with the swab
0.69 (0.40 to 1.19)
  Yes versus no Swab and tissue report totally 
different pathogens.
1.38 (0.66 to 2.89)
Wound duration (median split)* 941.48 5.802 3 0.121
  <56 days vs ≥56 days Swab>pathogens compared 
with the tissue
0.94 (0.43 to 2.04)
  <56 days vs ≥56 days Tissue>pathogens compared 
with the swab
1.75 (1.08 to 2.86)†
  <56 days vs ≥56 days Swab and tissue report totally 
different pathogens.
1.14 (0.59 to 2.17)
Log wound duration 
(continuous)*
944.97 2.318 3 0.509
Swab>pathogens compared 
with the tissue
0.95 (0.72 to 1.25)
Tissue>pathogens compared 
with the swab
0.88 (0.74 to 1.04)
Continued
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of the two sampling techniques may be related to: the 
tissue specimen providing a greater yield of organisms at 
collection; a lower rate of bacterial isolates dying during 
specimen transport; or differences in the way the microbi-
ology laboratory handled or reported the culture results. 
In settings where obtaining specimens by wound swab 
remains the standard method, until we determine the 
clinical impact of choosing tissue over swab sampling, we 
suggest examining methods to increase the yield from 
wound cultures.
For chronic wounds, there is no gold standard method 
of diagnosing infection. The minority of samples in our 
study that reported no pathogens may reflect either a false 
positive diagnosis of infection32 or a false negative culture 
related to the use of antimicrobial dressings and antibi-
otics prior to sampling. Alternatively, this finding may be 
related to: improper sampling technique (eg, not suffi-
ciently expressing tissue fluid in Levine’s technique26); 
transport media that fail to maintain the viability of 
wound swab pathogens; or a decision by the microbiology 
laboratory to report only pathogens that they deemed 
clinically significant.
A key clinical issue is how much, and what type of, infor-
mation on ulcer flora is useful for clinicians managing 
patients with an infected DFU. While clinicians want 
to optimally target their antibiotic therapy, providing 
microbiology reports listing many organisms, including 
likely non-pathogenic or unusual isolates present in low 
numbers, may confuse rather than aid decision-making. 
We do not know, based on our results or the available liter-
ature, if antibiotic treatment based on a more detailed 
microbiogram helps select an antimicrobial regimen that 
increases the likelihood of, or time to, resolution of infec-
tion, or the prevention of treatment-associated antibiotic 
resistance.
We found that when blinded clinicians were presented 
with tissue, as opposed to wound swab microbiology 
reports, they were more likely to recommend a change 
in antibiotic therapy. This suggests that the additional 
information tissue specimens provide could lead to 
more tailored antimicrobial regimens. We do not know, 
however, if this theoretical finding would be confirmed in 
clinical practice.
It is certainly important to adequately cover all likely 
pathogens in a potentially limb-threatening problem 
like diabetic foot infection. However, given the global 
emergency associated with antibiotic resistance related 
to overuse of this precious resource, we are cautious 
about recommending a wholesale change to adoption 
of tissue sampling as theoretically this is a technique that 
may lead to unnecessarily broad-spectrum prescribing. 
Furthermore, the bacterial flora in the wound at the 
time of sampling may differ from those present days later 
after empirical antibiotic therapy, when culture results 
are reported, potentially reducing the utility of this 
information.
This study has several strengths. We provided all centres 
with training on appropriate techniques for wound swab 
OR (95%  CI) AIC§ 
Reduction in
−2 Log L df P value
Swab and tissue report totally 
different pathogens.
0.93 (0.74 to 1.18)
Ordinal summary of isolates
Null model 917.72
Ulcer type*: any ischaemic 
versus neuropathic only
0.90 (0.61 to 1.33) 919.45 0.271 1 0.603
Ulcer grade 920.16 1.559 2 0.459
  Grade 2 versus grade 1 1.33 (0.82 to 2.15)
  Grade 3/4/5 versus grade 1 1.27 (0.78 to 2.07)
Previous antibiotic therapy*: yes 
versus no
1.25 (0.81 to 1.91) 918.56 1.154 1 0.283
Antimicrobial dressing*: yes 
versus no
0.76 (0.49 to 1.18) 918.16 1.553 1 0.213
Wound duration (median 
split)*: <56 days vs ≥56 days
1.56 (1.05 to 2.33) 914.62 5.097 1 0.024‡ 
Log wound duration 
(continuous)*
0.92 (0.80 to 1.05) 918.15 1.571 1 0.210
Based on the evaluable population n=395.
*Factors with missing data from the 28 (7.1%) patients with at least one missing data item.
‡Significant at the 5% level.
§Smaller is better.
AIC, Akaike information criterion.
Table 4 Continued 
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and tissue sampling in an effort to minimise between-
sample, and between-centre, differences. We prospec-
tively enrolled a large number of patients at many clinical 
sites using a carefully defined protocol that required 
obtaining contemporaneous dual specimens on each 
patient. The study also has high external validity; as we 
had minimal exclusion criteria, we recruited patients in 
usual practice settings, members of the attending clinical 
teams obtained the samples and the local laboratories 
processed the specimens.
There were, of course, some potential weaknesses of 
the study. There were differences among laboratories in 
tissue collection and sample culturing methods. These 
differences reflect the pragmatic nature of the study 
and ensure the results are generalisable to National 
Health Service centres and laboratories across England. 
Furthermore, only a small minority of patients (7%) were 
recruited from primary care (as opposed to specialty 
clinic or inpatient) centres. This limited our ability to 
investigate whether there was any difference in the extent 
of agreement in the reporting of pathogens between 
primary and secondary care sites.
Previous reports comparing wound swab with tissue 
specimens have been small, single-centre studies, and 
produced mixed results. One retrospective study of 89 
concomitantly obtained pairs of samples from 54 patients 
with DFUs (87% clinically infected)16 found that culture 
results of superficial wound swabs did not correlate well 
with those obtained from deep tissue, but they summarised 
their results in terms of predictive value for infection, for 
which there is no good evidence (deep tissue samples 
are an imperfect gold standard for diagnosing infec-
tion). Another study of 50 patients with a DFU ulcer17 
that compared culture results of tissue against wound 
swab specimens found that reports agreed in only 50% 
of patients. In another study of 56 patients with diabetic 
foot infection, grouped according to the PEDIS grading 
system,18 wound swab culturing identified all microorgan-
isms isolated from the corresponding deep tissue culture 
in 90% of grade 2 wounds, and in 41.4% and 41.2% for 
grade 3 and 4 wounds, respectively.
We believe our results demonstrate the increased yield 
from tissue compared with wound swab specimens; the 
maximum information would be available when reports 
from both samples are obtained. Combined with the 
currently available literature, this reinforces the recom-
mendations that tissue samples are preferred over swab 
specimens if one method is to be selected. However, 
current guidelines do not recognise the complementarity 
of information when both methods are used. What is still 
needed is further research on whether this increased 
information from tissue sampling results in more appro-
priate prescribing or better resolution of infection or 
improved wound healing. Furthermore, we need more 
research on whether molecular approaches that provide 
extended views of the microbiome in conjunction with 
new developments in near-patient testing improve clin-
ical outcomes and antibiotic stewardship. Results of 
these further studies would inform the most appropriate 
method of obtaining specimens from DFUs.
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